Zelira Therapeutics Limited (ZLDAF)
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC offering is ITURA, an advanced topical cream formulated to alleviate multiple symptoms such as numbness, tingling sensations, muscle cramps, reduced sensitivity, and pain frequently associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has cultivated strategic partnerships with prominent institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Incorporated in 2003, the company, which officially changed its name from Zelda Therapeutics Limited in December 2019, maintains its corporate headquarters in Perth, Australia.
Sector: Biotechnology
Industry: Biotechnology
Zelira Therapeutics Limited
- Not computed yet: no FINRA short interest has been matched to this float.
- 1.1K
- 4.49
Float 12.56M · FMP free float
The cost to borrow ZLDAF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
No price or settlement history available to chart.
Too few published sessions to show a reading in context.
FINRA's weekly alternative trading system (dark pool) volume for ZLDAF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.